One day after Sandoz and Amgen announced European launches of their biosimilar adalimumab products referencing Humira, Samsung Bioepis announced that it has launched its own biosimilar, Imraldi.
One day after Sandoz and Amgen announced European launches of their biosimilar adalimumab products referencing Humira, Samsung Bioepis announced that it has launched its own biosimilar, Imraldi. According to a company statement, the drug will become available today in major EU markets, though the company did not specify which nations would be first to receive access to the drug.
“The launch of Imraldi marks what we believe to be a landmark moment for Biogen and Samsung Bioepis and for European healthcare systems,” said Sang-Jin Pak, chief operating officer of Samsung Bioepis. “We hope Imraldi will play an important role widening choice and increasing competition in one of the most high-value areas of the biopharmaceuticals market.”
Imraldi’s launch marks Samsung Bioepis’ third EU market entry with an anti—tumor necrosis factor therapy; the company previously launched Benepali, an etanercept biosimilar, and Flixabi, an infliximab biosimilar.
Imraldi was approved in Europe in 2017 on the basis of a randomized, double-blind, 52-week phase 3 study in which 544 patients with moderate to severe rheumatoid arthritis for whom methotrexate was insufficient were randomized to receive either the biosimilar or the reference Humira.
At week 24, response rate for the American College of Rheumatology’s criteria for 20% improvement was 72.4% in the biosimilar arm versus 72.2% in the reference arm. Additionally, the safety profile of Imraldi was comparable to the reference up to week 24. At that timepoint, 254 patients receiving the reference product were randomized 1:1 to either continue to take reference adalimumab or switch to the biosimilar, while the original 254 patients taking Imraldi continued to receive the biosimilar.
The efficacy, safety, and immunogenicity profiles were comparable between all 3 treatment groups till week 52, and there were no treatment emergent issues or clinically-relevant immunogenicity precipitated by the switch.
Imraldi is also under the FDA’s consideration for US approval; in September 2018, Samsung Bioepis announced that the FDA had accepted a Biologics License Application for the drug.
Two approved adalimumab biosimilars are yet to launch in the European Union: Mylan’s Hulio and Boehringer Ingelheim’s Cyltezo. Neither developer has announced a target launch date for its product.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.